Redeye is encouraged to see Bong beating our expectations yet again. Q4 of 2022 shows further margin improvement and strong cash flows. Market conditions are still unpredictable and challenging. But Bong has demonstrated its ability to handle volatile market conditions, giving us confidence in raising our forecasts and valuation again.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/